Trial
NCT05367401
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Myelodysplastic Syndromes
Intervention
Sabatolimab
Why stopped
waiting for update from Study Lead
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-11